Free Trial

Rezolute (RZLT) Stock Price, News & Analysis

Rezolute logo
$4.46 +0.11 (+2.53%)
As of 04:00 PM Eastern

About Rezolute Stock (NASDAQ:RZLT)

Key Stats

Today's Range
$4.28
$4.71
50-Day Range
$3.11
$4.43
52-Week Range
$2.22
$6.19
Volume
2.22 million shs
Average Volume
636,057 shs
Market Capitalization
$381.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.83
Consensus Rating
Buy

Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

RZLT MarketRank™: 

Rezolute scored higher than 62% of companies evaluated by MarketBeat, and ranked 405th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rezolute has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rezolute has only been the subject of 2 research reports in the past 90 days.

  • Read more about Rezolute's stock forecast and price target.
  • Earnings Growth

    Earnings for Rezolute are expected to decrease in the coming year, from ($0.93) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rezolute is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rezolute is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rezolute has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Rezolute's valuation and earnings.
  • Percentage of Shares Shorted

    7.36% of the float of Rezolute has been sold short.
  • Short Interest Ratio / Days to Cover

    Rezolute has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Rezolute has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rezolute does not currently pay a dividend.

  • Dividend Growth

    Rezolute does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.36% of the float of Rezolute has been sold short.
  • Short Interest Ratio / Days to Cover

    Rezolute has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Rezolute has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rezolute has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Rezolute this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Rezolute to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,060,930.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    18.39% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rezolute's insider trading history.
Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

RZLT Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

RZLT Stock Analysis - Frequently Asked Questions

Rezolute's stock was trading at $4.90 at the start of the year. Since then, RZLT stock has decreased by 9.0% and is now trading at $4.46.
View the best growth stocks for 2025 here
.

Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05.

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO).

Company Calendar

Last Earnings
5/13/2025
Today
6/30/2025
Fiscal Year End
6/30/2025
Next Earnings (Estimated)
9/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RZLT
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.83
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+165.3%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.46 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.19 per share
Price / Book
2.04

Miscellaneous

Free Float
69,792,000
Market Cap
$381.42 million
Optionable
Optionable
Beta
1.04
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:RZLT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners